UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.

Search Articles

X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (8421) 8421
Newsletter (43) 43
Book Chapter (19) 19
Magazine Article (12) 12
Newspaper Article (10) 10
Dissertation (2) 2
Publication (2) 2
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (7445) 7445
cytarabine - administration & dosage (6601) 6601
male (4910) 4910
female (4867) 4867
science & technology (4553) 4553
life sciences & biomedicine (4489) 4489
antineoplastic combined chemotherapy protocols - therapeutic use (4191) 4191
middle aged (3981) 3981
adult (3849) 3849
aged (2665) 2665
oncology (2561) 2561
hematology (2502) 2502
adolescent (2251) 2251
leukemia, myeloid, acute - drug therapy (2102) 2102
remission induction (1830) 1830
treatment outcome (1497) 1497
cytarabine - therapeutic use (1487) 1487
cytarabine - adverse effects (1455) 1455
daunorubicin - administration & dosage (1440) 1440
antineoplastic combined chemotherapy protocols - adverse effects (1392) 1392
etoposide - administration & dosage (1344) 1344
antineoplastic combined chemotherapy protocols - administration & dosage (1276) 1276
child (1245) 1245
methotrexate - administration & dosage (1236) 1236
vincristine - administration & dosage (1218) 1218
cytarabine (1215) 1215
cyclophosphamide - administration & dosage (1210) 1210
chemotherapy (1076) 1076
prognosis (994) 994
animals (959) 959
combined modality therapy (956) 956
abridged index medicus (924) 924
acute disease (913) 913
doxorubicin - administration & dosage (904) 904
drug administration schedule (886) 886
child, preschool (873) 873
disease-free survival (832) 832
cancer (786) 786
recurrence (768) 768
prednisone - administration & dosage (726) 726
survival rate (707) 707
acute myeloid leukemia (666) 666
time factors (659) 659
survival analysis (639) 639
leukemia (632) 632
retrospective studies (629) 629
mitoxantrone - administration & dosage (618) 618
dose-response relationship, drug (617) 617
leukemia, myeloid - drug therapy (615) 615
cytarabine - pharmacology (613) 613
leukemia - drug therapy (594) 594
idarubicin - administration & dosage (591) 591
follow-up studies (588) 588
mice (578) 578
aged, 80 and over (568) 568
infant (565) 565
drug therapy, combination (559) 559
precursor cell lymphoblastic leukemia-lymphoma - drug therapy (558) 558
leukemia, myeloid, acute - mortality (547) 547
antineoplastic agents - administration & dosage (543) 543
young adult (525) 525
antimetabolites, antineoplastic - administration & dosage (497) 497
transplantation (489) 489
dexamethasone - administration & dosage (481) 481
thioguanine - administration & dosage (469) 469
bone marrow transplantation (467) 467
lymphoma, non-hodgkin - drug therapy (436) 436
mercaptopurine - administration & dosage (435) 435
hematopoietic stem cell transplantation (430) 430
transplantation, autologous (421) 421
leukemia, myeloid, acute - pathology (418) 418
cisplatin - administration & dosage (395) 395
prednisolone - administration & dosage (392) 392
care and treatment (385) 385
antineoplastic agents - therapeutic use (381) 381
medicine & public health (380) 380
prospective studies (376) 376
salvage therapy (374) 374
risk factors (355) 355
pharmacology & pharmacy (351) 351
carmustine - administration & dosage (349) 349
asparaginase - administration & dosage (341) 341
granulocyte colony-stimulating factor - administration & dosage (334) 334
injections, spinal (331) 331
melphalan - administration & dosage (330) 330
research (322) 322
age factors (321) 321
cytarabine - analogs & derivatives (315) 315
leukemia, myeloid, acute - genetics (315) 315
pediatrics (314) 314
dosage and administration (313) 313
stem cells (313) 313
clinical trials as topic (310) 310
bone marrow - pathology (304) 304
vidarabine - analogs & derivatives (303) 303
leukemia, myeloid, acute - therapy (291) 291
drug evaluation (277) 277
leukemia, lymphoid - drug therapy (274) 274
myelodysplastic syndromes - drug therapy (263) 263
vidarabine - administration & dosage (260) 260
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (7698) 7698
Japanese (517) 517
German (114) 114
Chinese (97) 97
Spanish (91) 91
French (87) 87
Polish (73) 73
Russian (67) 67
Italian (21) 21
Czech (15) 15
Hungarian (12) 12
Portuguese (8) 8
Danish (6) 6
Hebrew (3) 3
Arabic (2) 2
Dutch (2) 2
Norwegian (2) 2
Serbian (2) 2
Slovak (2) 2
Croatian (1) 1
Turkish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The Lancet (British edition), ISSN 0140-6736, 2010, Volume 376, Issue 9757, pp. 2009 - 2017
Summary Background Although survival of children with acute lymphoblastic leukaemia has improved greatly in the past two decades, the outcome of those who... 
Internal Medicine | Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Recurrence | Cyclophosphamide - administration & dosage | Humans | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Child, Preschool | Infant | Male | Precursor Cell Lymphoblastic Leukemia-Lymphoma - drug therapy | Vincristine - administration & dosage | Female | Leukocyte Count | Child | Idarubicin - therapeutic use | Mitoxantrone - therapeutic use | Dexamethasone - administration & dosage | Risk Assessment | Kaplan-Meier Estimate | Mercaptopurine - administration & dosage | Etoposide - administration & dosage | Treatment Outcome | United Kingdom | Vidarabine - analogs & derivatives | Cytarabine - administration & dosage | Polyethylene Glycols - administration & dosage | Asparaginase - administration & dosage | Disease-Free Survival | Antibiotics, Antineoplastic - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Adolescent | Methotrexate - administration & dosage | Vidarabine - administration & dosage | Complications and side effects | Dosage and administration | Acute lymphocytic leukemia | Drug therapy | Patient outcomes | Mitoxantrone hydrochloride | Studies | Design | Medical research | Chemotherapy | Databases | Cytogenetics | Cancer therapies | Cancer | Ovarian cancer | Index Medicus | Abridged Index Medicus
Journal Article
Cancer, ISSN 0008-543X, 12/2014, Volume 120, Issue 23, pp. 3660 - 3668
Journal Article
British journal of haematology, ISSN 0007-1048, 11/2014, Volume 167, Issue 3, pp. 394 - 401
Summary Children and adolescents with Burkitt Lymphoma (BL) and combined central nervous system (CNS) and bone marrow involvement still have a poor prognosis... 
Burkitt leukaemia | children | chemotherapy | rituximab | Burkitt lymphoma | Rituximab | Chemotherapy | Children | Life Sciences & Biomedicine | Hematology | Science & Technology | Cyclophosphamide - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Humans | Antibodies, Monoclonal, Murine-Derived - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Consolidation Chemotherapy | Cytarabine - adverse effects | Genes, myc | Typhlitis - chemically induced | Lymphoma, B-Cell - genetics | Cyclophosphamide - adverse effects | Immunotherapy | Burkitt Lymphoma - genetics | Vincristine - administration & dosage | Female | Maintenance Chemotherapy | Child | Burkitt Lymphoma - drug therapy | Doxorubicin - administration & dosage | Lymphoma, B-Cell - drug therapy | Prednisone - administration & dosage | Etoposide - adverse effects | Prednisone - adverse effects | Drug Administration Schedule | Kaplan-Meier Estimate | Etoposide - administration & dosage | Remission Induction | Cytarabine - administration & dosage | Disease-Free Survival | Methotrexate - adverse effects | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Bone Marrow - pathology | Adolescent | Vincristine - adverse effects | Methotrexate - administration & dosage | Infusions, Intravenous | Antibodies, Monoclonal, Murine-Derived - adverse effects | Central Nervous System Neoplasms - drug therapy | Doxorubicin - adverse effects | Lymphomas | Leukemia | Central nervous system | Cancer | Index Medicus | Burkitt Leukaemia | Burkitt Lymphoma | adolescents
Journal Article
The lancet oncology, ISSN 1470-2045, 07/2014, Volume 15, Issue 8, pp. 809 - 818
Journal Article
Blood, ISSN 1528-0020, 02/2015, Volume 125, Issue 9, pp. 1403 - 1410
Journal Article
JNCI : Journal of the National Cancer Institute, ISSN 0027-8874, 08/2014, Volume 106, Issue 8, pp. dju170 - dju170
This sixteenth biannual report of the Cochrane Haematological Malignancies Group highlights recently published randomized controlled trials (RCTs) in the field... 
Life Sciences & Biomedicine | Oncology | Science & Technology | Hematologic Neoplasms - therapy | Cyclophosphamide - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Lymphoma, Follicular - drug therapy | Primary Myelofibrosis | Nitrogen Mustard Compounds - administration & dosage | Humans | Pyrazines - administration & dosage | Antibodies, Monoclonal, Murine-Derived - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Cytarabine - adverse effects | Cyclophosphamide - adverse effects | Melphalan - adverse effects | Vincristine - administration & dosage | Boronic Acids - administration & dosage | Carmustine - adverse effects | Doxorubicin - administration & dosage | Lymphoma, Non-Hodgkin - drug therapy | Prednisone - administration & dosage | Bortezomib | Etoposide - adverse effects | Lymphoma, Large B-Cell, Diffuse - drug therapy | Prednisone - adverse effects | Drug Administration Schedule | Lymphoma, Mantle-Cell - drug therapy | Rituximab | Etoposide - administration & dosage | Nitrogen Mustard Compounds - adverse effects | Cytarabine - administration & dosage | Randomized Controlled Trials as Topic | Melphalan - administration & dosage | Pyrazoles - administration & dosage | Bendamustine Hydrochloride | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Quality of Life | Vincristine - adverse effects | Antibodies, Monoclonal, Murine-Derived - adverse effects | Doxorubicin - adverse effects | Carmustine - administration & dosage | Index Medicus
Journal Article
British journal of haematology, ISSN 0007-1048, 01/2016, Volume 172, Issue 1, pp. 80 - 88
Summary Intensive chemotherapy regimens containing cytarabine have substantially improved remission durability and overall survival in younger adults with... 
secondary malignancy | treatment | mantle cell lymphoma | methotrexate | hyper‐CVAD | Secondary malignancy | Treatment | Hyper-CVAD | Methotrexate | Mantle cell lymphoma | Life Sciences & Biomedicine | Hematology | Science & Technology | Cyclophosphamide - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Follow-Up Studies | Humans | Middle Aged | Lymphoma, Mantle-Cell - pathology | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Dexamethasone - adverse effects | Male | Cytarabine - adverse effects | Cyclophosphamide - adverse effects | Neoplasms, Second Primary - chemically induced | Myelodysplastic Syndromes - chemically induced | Aged, 80 and over | Vincristine - administration & dosage | Adult | Female | Leukemia, Myeloid, Acute - chemically induced | Doxorubicin - administration & dosage | Rituximab - adverse effects | Dexamethasone - administration & dosage | Drug Administration Schedule | Lymphoma, Mantle-Cell - drug therapy | Cytarabine - administration & dosage | Rituximab - administration & dosage | Methotrexate - adverse effects | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Vincristine - adverse effects | Methotrexate - administration & dosage | Aged | Doxorubicin - adverse effects | Care and treatment | Chemotherapy | Oncology, Experimental | Clinical trials | Lymphomas | Research | Cancer | Index Medicus | hyper-CVAD
Journal Article
Cancer, ISSN 0008-543X, 02/2014, Volume 120, Issue 3, pp. 373 - 380
Journal Article
Annals of oncology, ISSN 0923-7534, 5/2008, Volume 19, Issue 5, pp. 958 - 963
Aim: To analyze toxicity, response and outcome of a phase II trial with intensive chemotherapy plus autologous stem-cell transplantation (ASCT) for young... 
Autologous stem-cell transplantation | Peripheral T-cell lymphoma | Prognosis | Life Sciences & Biomedicine | Oncology | Science & Technology | Cyclophosphamide - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Follow-Up Studies | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Transplantation, Autologous | Cytarabine - adverse effects | Cyclophosphamide - adverse effects | Cisplatin - administration & dosage | Vincristine - administration & dosage | Adult | Female | Lymphoma, T-Cell, Peripheral - classification | Doxorubicin - administration & dosage | Lymphoma, T-Cell, Peripheral - drug therapy | Prednisone - administration & dosage | Etoposide - adverse effects | Prednisone - adverse effects | Etoposide - administration & dosage | Treatment Outcome | Combined Modality Therapy | Remission Induction | Cytarabine - administration & dosage | Neoplasms, Second Primary - epidemiology | Disease-Free Survival | Melphalan - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Cisplatin - adverse effects | Vincristine - adverse effects | Lymphoma, T-Cell, Peripheral - surgery | Aged | Transplantation Conditioning | Peripheral Blood Stem Cell Transplantation | Doxorubicin - adverse effects | Carmustine - administration & dosage | Index Medicus
Journal Article
JNCI : Journal of the National Cancer Institute, ISSN 1460-2105, 09/2012, Volume 104, Issue 18, pp. 1386 - 1395
Treatment of acute lymphoblastic leukemia (ALL) has included the use of prophylactic cranial irradiation in up to 20% of children with high-risk disease... 
Life Sciences & Biomedicine | Oncology | Science & Technology | Multivariate Analysis | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Age Factors | Humans | Precursor Cell Lymphoblastic Leukemia-Lymphoma - psychology | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Child, Preschool | Dexamethasone - adverse effects | Infant | Male | Cytarabine - adverse effects | Patient Selection | Hydrocortisone - administration & dosage | Precursor Cell Lymphoblastic Leukemia-Lymphoma - drug therapy | Time Factors | Attention - drug effects | Vincristine - administration & dosage | Female | Child | Injections, Spinal | Prednisone - administration & dosage | Dexamethasone - administration & dosage | Prednisone - adverse effects | Drug Administration Schedule | Risk Factors | Mercaptopurine - administration & dosage | Mercaptopurine - adverse effects | Logistic Models | Treatment Outcome | Cognition - drug effects | Cranial Irradiation - adverse effects | Remission Induction | Cytarabine - administration & dosage | Intelligence Tests | Methotrexate - adverse effects | Hydrocortisone - adverse effects | Adolescent | Sex Factors | Vincristine - adverse effects | Methotrexate - administration & dosage | Intelligence - drug effects | Care and treatment | Patient outcomes | Acute lymphocytic leukemia | Research | Cognition disorders | Risk factors | Cancer in children | Chemotherapy | Cognition & reasoning | Patients | Leukemia | Children & youth | Index Medicus
Journal Article